Cutting-Edge Concepts in HIV Care: Long-Acting Therapies
Listen to Paul E. Sax, MD, discuss what’s new in long-acting injectables for HIV treatment.
Decera Clinical Education Infectious Disease Podcast · Paul E. Sax MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:
- Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
- Risk factors for virologic failure of LA CAB + RPV
- The ATLAS-2M study
- Combined clinical trials of LA CAB + RPV
- Practical considerations for LA CAB + RPV
- Implementation of LA CAB + RPV
- Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
- Supporting candidates for LA antiretroviral therapy (ART)
- Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
- Future LA ART
- The investigational LA HIV capsid inhibitor lenacapavir (LEN)
- LEN resistance from the CAPELLA and CALIBRATE studies
- LEN injection-site reactions in the CAPELLA and CALIBRATE studies
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
http://bit.ly/3Gh9AKG
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.